NASH therapeutic (Kirrhos Pharmaceuticals)

N/A

Report date: 2025/01/26 19:10:41
NME

Base Information

Drug NameNASH therapeutic (Kirrhos Pharmaceuticals)
Drug Alias NameFGF-21 Inhibitor (Kirrhos Pharmaceutical)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor 21 inhibitors
TargetsFibroblast growth factor 21
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKirrhos Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesKirrhos Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A